These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 14982308

  • 1. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma.
    Eur J Cancer Care (Engl); 2003 Dec; 12(4):306-7. PubMed ID: 14982308
    [No Abstract] [Full Text] [Related]

  • 2. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK, Zhu J, Ke XY, Wang HQ, Shen ZX, Yu SY, Liu T, Shi XL.
    Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
    [Abstract] [Full Text] [Related]

  • 3. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
    van Meerten T, Hagenbeek A.
    Neth J Med; 2009 Dec; 67(7):251-9. PubMed ID: 19687518
    [Abstract] [Full Text] [Related]

  • 4. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ, Zhang QY, Chen DF, Guan XJ, Zhang BL, Ma J.
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [Abstract] [Full Text] [Related]

  • 5. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B, Santos ES.
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [Abstract] [Full Text] [Related]

  • 6. Antibody therapy for non-Hodgkin's lymphoma.
    Ansell SM.
    Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
    [Abstract] [Full Text] [Related]

  • 7. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 9. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
    Iguchi T, Miyazawa K, Okabe S, Kawakubo K, Shimamoto T, Kuriyama Y, Ito Y, Kimura Y, Ohyashiki K, Serizawa H, Iwaya K, Mukai K.
    Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
    [Abstract] [Full Text] [Related]

  • 10. Rituximab (Rituxan/MabThera): the first decade (1993-2003).
    Grillo-López AJ.
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):767-79. PubMed ID: 14686699
    [Abstract] [Full Text] [Related]

  • 11. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
    Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM.
    Clin Cancer Res; 2004 Aug 15; 10(16):5327-34. PubMed ID: 15328168
    [Abstract] [Full Text] [Related]

  • 12. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma.
    Nakai S, Masaki T, Shintani T, Deguchi A, Kimura Y, Himoto T, Kurokohchi K, Watanabe S, Kuriyama S.
    Oncol Rep; 2005 Jun 15; 13(6):1065-8. PubMed ID: 15870922
    [Abstract] [Full Text] [Related]

  • 13. [Maintenance therapy with rituximab].
    Krankenpfl J; 2005 Jun 15; 43(7-10):222-4. PubMed ID: 16515293
    [No Abstract] [Full Text] [Related]

  • 14. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma.
    Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouafia F, Alhusein Q, Antal D, Salles G, Coiffier B.
    Bone Marrow Transplant; 2004 May 15; 33(9):921-3. PubMed ID: 15034544
    [Abstract] [Full Text] [Related]

  • 15. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR, Bonavida B.
    Oncogene; 2005 Mar 24; 24(13):2121-43. PubMed ID: 15789036
    [Abstract] [Full Text] [Related]

  • 16. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschütz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG.
    Cancer Invest; 2006 Oct 24; 24(6):593-600. PubMed ID: 16982464
    [Abstract] [Full Text] [Related]

  • 17. Complete molecular remission induced by rituximab in a patient with diffuse large cell lymphoma.
    Zinzani PL, Bendandi M, Gamberi B, Magagnoli M, Gherlinzoni F, Tura S.
    Haematologica; 2000 Apr 24; 85(4):437-8. PubMed ID: 10756377
    [No Abstract] [Full Text] [Related]

  • 18. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
    Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ.
    Clin Cancer Res; 2007 Oct 15; 13(20):6168-74. PubMed ID: 17947483
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of rituximab and its clinical use: thought for the best use?
    Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C.
    Crit Rev Oncol Hematol; 2007 Apr 15; 62(1):43-52. PubMed ID: 17287129
    [Abstract] [Full Text] [Related]

  • 20. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice.
    Mineo JF, Scheffer A, Karkoutly C, Nouvel L, Kerdraon O, Trauet J, Bordron A, Dessaint JP, Labalette M, Berthou C, Labalette P.
    Invest Ophthalmol Vis Sci; 2008 Nov 15; 49(11):4738-45. PubMed ID: 18552383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.